<DOC>
	<DOCNO>NCT00883051</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety range oral dose COL-144 treat migraine headache , order select dose dose evaluation .</brief_summary>
	<brief_title>Dose-ranging Study Oral COL-144 Acute Migraine Treatment</brief_title>
	<detailed_description>Migraine common chronic neurological disorder characterize recurrent disable episode moderate severe headache accompany nausea , vomit , photophobia , phonophobia . Acute pharmacologic therapy migraine aim terminate attack reduce severity. , Analgesics commonly use , ineffective , triptans . Since triptans contraindicate patient coronary artery disease , uncontrolled hypertension , cerebrovascular disease alternative medication require patient simple analgesic work . COL-144 vasoconstrictor activity clinically relevant concentration might meet need . COL-144 effective give intravenously placebo-controlled dose-ranging study . This study investigate dose oral COL-144 effective acute treatment migraine headache .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Patients migraine without aura fulfil IHS diagnostic criterion 1.1 1.2.1 ( 2004 ) History migraine least 1 year Migraine onset age 50 year History 1 8 migraine attack per month Male female patient age 18 65 year Female patient childbearing potential must use highly effective form contraception ( e.g. , combined oral contraceptive , IUD , abstinence , vasectomized partner ) Able willing give write informed consent Able willing complete migraine diary card record detail attack treat study medication History life threaten intolerable adverse reaction triptan Use prescription migraine prophylactic drug within 15 day ( 30 day flunarizine ) prior Screening Visit study participation Using herbal preparation ( e.g. , feverfew , butterbur ) migraine prophylaxis Using 5HT reuptake inhibitor Using drug know inhibit CYP450 enzymes ( see Appendix 2 detail ) Pregnant breastfeed woman Women childbearing potential use highly effective contraception History evidence coronary artery disease , ischemic hemorrhagic stroke , epilepsy condition place patient increase risk seizure History hypertension ( control uncontrolled ) History orthostatic hypotension Current use hemodynamically active cardiovascular drug History within previous 3 year current evidence abuse drug , prescription illicit , alcohol Significant renal hepatic impairment Previous participation clinical trial Participation clinical trial experimental drug device previous 30 day Any medical condition laboratory test judgment investigator make patient unsuitable study Known Hepatitis B C HIV infection Patients employee sponsor Relatives , staff directly reporting , investigator Patients know hypersensitivity COL144 , 5HT1F receptor agonist excipient COL144 drug product Patients treat study medication COL MIG201 study ( Patients screen treat protocol exclude )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>COL-144</keyword>
	<keyword>acute treatment</keyword>
	<keyword>migraine</keyword>
</DOC>